Published in:
01-06-2019 | Dasabuvir | Hepatitis C (H Vargas and S Flamm, Section Editors)
Acute HCV Treatment: What Should We Do in the DAA Era?
Published in: Current Hepatology Reports | Issue 2/2019
Login to get accessAbstract
Purpose of Review
Acute hepatitis C infection is a growing concern in the USA, especially in light of the opioid epidemic. Prior treatment data consisted of trials in patients receiving interferon-based regimens. There is now emerging evidence regarding the safety and efficacy of direct-acting antivirals for the treatment of acute hepatitis C. This review summarizes the current evidence on the treatment of acute HCV in the DAA era.
Recent Findings
Certain populations, such as people who inject drugs, or HIV-positive men who have sex with men, may benefit from early treatment of acute HCV. As compared with chronic hepatitis C, shorter durations of treatment appear highly effective in acute infection, resulting in reduced viral transmission, as well as potentially reduced overall costs of care related to this disease.
Summary
Further studies are needed to clarify the optimal drug combinations and treatment durations to achieve sustained virologic response in these patients.